S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:MBIO

Mustang Bio Stock Forecast, Price & News

$2.08
-0.10 (-4.59%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.99
$2.16
50-Day Range
$2.08
$2.88
52-Week Range
$1.99
$5.22
Volume
1.29 million shs
Average Volume
1.83 million shs
Market Capitalization
$194.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.6
30 days | 90 days | 365 days | Advanced Chart
Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.


Mustang Bio logo

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBIO
Fax
N/A
Employees
62
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.31 per share

Profitability

Net Income
$-60.01 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
91,466,000
Market Cap
$194.33 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

704th out of 1,391 stocks

Pharmaceutical Preparations Industry

331st out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

Is Mustang Bio a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mustang Bio stock.
View analyst ratings for Mustang Bio
or view top-rated stocks.

How has Mustang Bio's stock price been impacted by Coronavirus?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBIO shares have decreased by 11.5% and is now trading at $2.08.
View which stocks have been most impacted by COVID-19
.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Mustang Bio
.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) posted its earnings results on Friday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01.
View Mustang Bio's earnings history
.

What price target have analysts set for MBIO?

4 Wall Street analysts have issued 1 year target prices for Mustang Bio's shares. Their forecasts range from $7.00 to $13.00. On average, they anticipate Mustang Bio's stock price to reach $10.33 in the next year. This suggests a possible upside of 396.8% from the stock's current price.
View analysts' price targets for Mustang Bio
or view top-rated stocks among Wall Street analysts.

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu Biopharma (AYTU) and (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.49%), Geode Capital Management LLC (1.47%), Two Sigma Advisers LP (1.35%), Dimensional Fund Advisors LP (1.16%), Two Sigma Investments LP (1.04%) and GSA Capital Partners LLP (0.61%). Company insiders that own Mustang Bio stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends for Mustang Bio
.

Which institutional investors are selling Mustang Bio stock?

MBIO stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Investments LP, Two Sigma Advisers LP, Oppenheimer & Co. Inc., California State Teachers Retirement System, and Jane Street Group LLC.
View insider buying and selling activity for Mustang Bio
or view top insider-selling stocks.

Which institutional investors are buying Mustang Bio stock?

MBIO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Goldman Sachs Group Inc., Geode Capital Management LLC, Telemetry Investments L.L.C., BlackRock Inc., and Hsbc Holdings PLC. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman.
View insider buying and selling activity for Mustang Bio
or or view top insider-buying stocks.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $2.08.

How much money does Mustang Bio make?

Mustang Bio has a market capitalization of $194.33 million. The company earns $-60.01 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Mustang Bio have?

Mustang Bio employs 62 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is www.mustangbio.com.

Where are Mustang Bio's headquarters?

Mustang Bio is headquartered at 377 PLANTATION STREET, WORCESTER MA, 01605.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at (781) 652-4500 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.